Revolution Medicines, Inc.
RVMDW· Nasdaq
RVMDWRevolution Medicines, Inc.
Filed Aug 7, 2024 · 10-Q · 38 days after period end · 0000950170-24-092783
| Metric | Q2 2024 | Q2 2020 | Q2 2019 |
|---|---|---|---|
| Revenue | $0.00 | $10.03M | $12.28M |
| Net Income | -$133.23M | -$27.22M | -$10.12M |
| EPS Diluted | -$0.81 | -$0.46 | -$4.85 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Revolution Medicines, Inc. · CIK 1628171 · Engraved from SEC EDGAR
ended Jun 30, 2024 · filed Aug 7, 2024 · 38 d after period end
